REGENERON PHARMACEUTICALS, INC.·4

May 17, 5:57 PM ET

SCHLEIFER LEONARD S 4

4 · REGENERON PHARMACEUTICALS, INC. · Filed May 17, 2024

Insider Transaction Report

Form 4
Period: 2024-05-17
SCHLEIFER LEONARD S
DirectorCEO and President10% Owner
Transactions
  • Sale

    Common Stock

    2024-05-17$979.22/sh22,687$22,215,564467,020 total
  • Sale

    Common Stock

    2024-05-17$980.07/sh143$140,150466,877 total
Holdings
  • Common Stock

    (indirect: By 401(k))
    5,932
  • Common Stock

    (indirect: By Trust)
    64,985
  • Common Stock

    (indirect: 2023 GRAT)
    157,552
Footnotes (3)
  • [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024.
  • [F2]Represents volume-weighted average price of sales of 22,687 shares of Company stock on May 17, 2024 at prices ranging from $979.00 to $979.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2024 at each separate price.
  • [F3]Represents volume-weighted average price of sales of 143 shares of Company stock on May 17, 2024 at prices ranging from $980.01 to $980.20. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2024 at each separate price.

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT